Cardiovascular events are not significantly decreased with edetate disodium chelation in patients with CAD and history of myocardial infarction and diabetes.

Rising Pharma Holdings, Inc., d/b/a Rising Pharmaceuticals, Inc. (“Rising”) announced commercial availability of Edetate calcium disodium injection. Access to Rising’s product continues despite a ...

The study, published in JAMA, revealed that EDTA-based chelation decreased median blood lead levels by 61% from baseline in patients with diabetes and prior MI, however, it failed to reduce major ...

Also, the chelation therapy involved not just the chelating agent disodium EDTA, but also high-dose vitamin C, magnesium, the anesthetic procaine and the blood thinner heparin. There was a high ...